3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Urologic Neoplasms
1
Radiation Injuries
1
Patient Satisfaction
1
Patient Acceptance of Health Care
1
Interventions
Docetaxel
205
Prednisone
151
enzalutamide
128
Gemcitabine
123
Radiotherapy
117
Sunitinib
112
Cisplatin
103
Leuprolide
98
pembrolizumab
96
Abiraterone Acetate
94
bicalutamide
87
Nivolumab
85
Goserelin
83
Sorafenib
80
Paclitaxel
79
Carboplatin
77
Everolimus
72
Bevacizumab
71
Magnetic Resonance Spectroscopy
66
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
61
pazopanib
56
radium Ra 223 dichloride
50
Ipilimumab
49
Zoledronic Acid
47
Cyclophosphamide
44
Radiosurgery
43
Filgrastim
42
abiraterone
41
gallium 68 PSMA-11
40
Surveys and Questionnaires
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
delta 24-sterol reductase
×
Genitourinary
×
Clear all
NCT04590976
2023-02-08
IP5-MATTER
Imperial College London
Completed
320 enrolled